U.S. markets open in 2 hours 21 minutes

Medigene AG (MDGEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.51+0.33 (+6.37%)
At close: 11:06AM EST

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 200033 0
http://www.medigene.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees123

Key Executives

NameTitlePayExercisedYear Born
Dr. Dolores J. SchendelCEO, Chief Scientific Officer & Member of Exec. Management BoardN/AN/AN/A
Mr. Axel Sven MalkomesCFO, Chief Bus. Devel. Officer & Member of Exec. Management BoardN/AN/AN/A
Dr. Kai PinkernellChief Medical Officer, Chief Devel. Officer & Member of Exec. Management BoardN/AN/AN/A
Dr. Ernst-Ludwig WinnackerCo-Founder & Chairman Scientific Advisory BoardN/AN/A1941
Dr. Gary Anthony Waanders Ph.D.VP of Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal and Institute for Research in Immunology and Cancer — Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Corporate Governance

Medigene AG’s ISS Governance QualityScore as of December 1, 2020 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.